Pfizer’s Haleon HLN Stock Holding History

Pfizer’s Portfolio HLN Stock Details HLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-197,228,952	Closed	-$1.88B	–	23
2024 Q4	$1.88B	Buy	+197,228,952	New	+$1.93B	72.59%	1

Other funds holding HLN

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Harding Loevner Bridgewater, New Jersey $10.6B AUM 19.39% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Sculptor Capital New York $12.3B AUM 40.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

DLA

Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return

Aristotle Capital Management Los Angeles, California $47.7B AUM 13.92% 1-Year Est. Return

Pfizer's HLN Position: Q1 2025 in Review

Pfizer sold out of Haleon (HLN) in Q1 2025, closing a stake of 197,228,952 shares — an estimated $1.88B sold.

Pfizer first reported a position in HLN in Q4 2024 and held it in 1 quarter. The position peaked at $1.88B in Q4 2024. 599 funds tracked by Wall St. Rank hold HLN as of Q1 2025.

Pfizer reported no remaining Haleon position as of Q1 2025 after selling out during the quarter.
Pfizer sold 197,228,952 Haleon shares in Q1 2025, an estimated $1.88B.
Pfizer first reported a position in Haleon in Q4 2024 and held it in 1 quarter.
Pfizer's Haleon position peaked at $1.88B in Q4 2024.
599 funds tracked by Wall St. Rank held Haleon as of Q1 2025.

Based on Pfizer's 13F filing for Q1 2025, filed 13 May 2025.